Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI4E9K)

Drug Name

MLN0264 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Gastrointestinal cancer	2C11	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Guanylyl cyclase C (GUCY2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Linaclotide	DM4EGV0	Irritable bowel syndrome	DD91.0	Approved	[3]
MD-1100	DM4IAKR	Constipation	DD91.1	Approved	[4]
Plecanatide	DMKEX7O	Chronic idiopathic constipation	DC32	Approved	[5]
SP-333	DM2UKJV	Ulcerative colitis	DD71	Phase 2	[6]
PF-07062119	DME3BJL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT02202759) A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction. U.S. National Institutes of Health.
2	J Clin Oncol 31, 2013 (suppl; abstr TPS3646).
3	Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
4	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395.